<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACETAZOLAMIDE- acetazolamide tablet </strong><br>Golden State Medical Supply, Inc.<br></p></div>
<h1>
<span class="Bold">AcetaZOLAMIDE </span><br><span class="Bold">Tablet USP</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60e2ee29-78a5-4c25-8caa-1290ce686744"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_5ea5e4e0-df98-485d-9fa3-7a66c9df9156"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Acetazolamide, an inhibitor of the enzyme carbonic anhydrase is a white to faintly yellowish white crystalline, odorless powder, weakly acidic, very slightly soluble in water and slightly soluble in alcohol. The chemical name for acetazolamide is <span class="Italics">N</span>-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)-acetamide and has the following chemical structure:</p>
<div class="Figure">
<a name="id345"></a><img alt="Chemical Structure - AcetaZolamide " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ceb5cac3-bbfb-42fa-8b29-c0ef5ed0913c&amp;name=ceb5cac3-bbfb-42fa-8b29-c0ef5ed0913c-01.jpg">
</div>
<p>Molecular Weight: 222.25<br>Molecular Formula: C<span class="Sub">4</span>H<span class="Sub">6</span>N<span class="Sub">4</span> O<span class="Sub">3</span>S<span class="Sub">2</span></p>
<p>Acetazolamide is available as oral tablets containing 125 mg and 250 mg of acetazolamide, respectively, and the following inactive ingredients: corn starch, gelatin, glycerin, lactose monohydrate, magnesium stearate, purified water, sodium starch glycolate and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_36269f86-e4c2-4a0f-afab-cf7f3bbee79e"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g., some types of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>), in the treatment of certain <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span> (e.g., <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>) and in the promotion of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in instances of abnormal <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> (e.g., cardiac <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>).</p>
<p>Acetazolamide is not a mercurial diuretic. Rather, it is a nonbacteriostatic sulfonamide possessing a chemical structure and pharmacological activity distinctly different from the bacteriostatic sulfonamides.</p>
<p>Acetazolamide is an enzyme inhibitor that acts specifically on carbonic anhydrase, the enzyme that catalyzes the reversible reaction involving the hydration of <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and the <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> of carbonic acid. In the eye, this inhibitory action of acetazolamide decreases the secretion of aqueous humor and results in a drop in intraocular pressure, a reaction considered desirable in cases of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and even in certain nonglaucomatous conditions. Evidence seems to indicate that acetazolamide has utility as an adjuvant in the treatment of certain dysfunctions of the central nervous system (e.g., <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>). Inhibition of carbonic anhydrase in this area appears to retard abnormal, paroxysmal, excessive discharge from central nervous system neurons. The <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> of acetazolamide is due to its action in the kidney on the reversible reaction involving hydration of <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> of carbonic acid. The result is renal loss of HCO<span class="Sub">3</span> ion, which carries out sodium, water, and potassium. Alkalinization of the urine and promotion of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> are thus effected. Alteration in <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> metabolism occurs due to increased reabsorption of <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> by the renal tubules as a result of urinary alkalinization.</p>
<p>Placebo-controlled clinical trials have shown that <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of acetazolamide at a dose of 250 mg every eight to 12 hours (or a 500 mg controlled-release capsule once daily) before and during rapid ascent to altitude results in fewer and/or less severe symptoms (such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>) of acute mountain sickness (AMS). Pulmonary function (e.g., minute ventilation, expired <span class="product-label-link" type="condition" conceptid="4147814" conceptname="Vital capacity">vital capacity</span>, and peak flow) is greater in the acetazolamide treated group, both in subjects with AMS and asymptomatic subjects. The acetazolamide treated climbers also had less difficulty in sleeping.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_23499b71-b186-462f-bc33-55df1cc86012"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For adjunctive treatment of: <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> due to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>; drug-induced <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; centrencephalic epilepsies (<span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span>, unlocalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>); chronic simple (open-angle) <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, secondary <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and preoperatively in acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_09d3f2af-f1b0-43ab-94c5-00612200cb3b"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in <span class="product-label-link" type="condition" conceptid="4108257" conceptname="Metabolic acidosis, NAG, acidifying salts">hyperchloremic acidosis</span>. It is contraindicated in patients with cirrhosis because of the risk of development of <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>.</p>
<p>Long-term administration of acetazolamide is contraindicated in patients with chronic noncongestive angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> since it may permit organic closure of the angle to occur while the worsening <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is masked by lowered intraocular pressure.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_59defe06-7633-472e-a881-57cfe2b460ce"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="id_2c4f0567-d290-49bf-8be5-90738615a4d1"></a><a name="section-6.1"></a><p></p>
<h2></h2>
<p class="First">Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>. Sensiti-zations may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or other serious reactions occur, discontinue use of this drug.</p>
<p>Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_6a709fde-ded2-4615-b2a4-c03d02200aa1"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_a9aff8f7-24eb-4cd7-b714-3a7aeade417a"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Increasing the dose does not increase the <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and may increase the incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and/or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. Increasing the dose often results in a decrease in <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. Under certain circumstances, however, very large doses have been given in conjunction with other diuretics in order to secure <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in complete refractory failure.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_41eea5c9-a960-4dac-9b3f-0458546412c3"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Adverse reactions common to all sulfonamide derivatives may occur: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>), <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Precaution is advised for early detection of such reactions and the drug should be discontinued and appropriate therapy instituted.</p>
<p>In patients with pulmonary obstruction or <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span> where alveolar ventilation may be impaired, acetazolamide, which may precipitate or aggravate <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, should be used only with caution.</p>
<p>Gradual ascent is desirable to try to avoid acute mountain sickness. If rapid ascent is undertaken and acetazolamide tablets are used, it should be noted that such use does not obviate the need for prompt descent if severe forms of high altitude sickness occur, i.e., high altitude <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> (HAPE) or high altitude <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>.</p>
<p>Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported (see <span class="Bold"><a href="#i4i_warnings_id_59defe06-7633-472e-a881-57cfe2b460ce">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_bec50eca-a9c3-4603-9b4f-c2bb4164a584"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">To monitor for hematologic reactions common to all sulfonamides, it is recommended that a baseline CBC and platelet count be obtained on patients prior to initiating acetazolamide tablet therapy and at regular intervals during therapy. If significant changes occur, early discontinuance and institution of appropriate therapy are important. Periodic monitoring of serum electrolytes is recommended.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_2f48d14e-fe16-4494-bc1c-22464453f50e"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenisis, Mutagensis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of acetazolamide have not been conducted. In a bacterial mutagenicity assay, acetazolamide was not mutagenic when evaluated with and without metabolic activation.</p>
<p>The drug had no effect on fertility when administered in the diet to male and female rats at a daily intake of up to 4 times the recommended human dose of 1000 mg in a 50 kg individual.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_9e9f21a1-dd98-4a42-a533-60700db48414"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_8e6c2c3c-c586-45b0-964f-27eca5c944e1"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effect</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ac79142-df0b-40a5-8060-9690d3752bf6"></a><a name="section-7.5.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category C</span></h4>
<p class="First">Acetazolamide, administered orally or parenterally, has been shown to be teratogenic (defects of the limbs) in mice, rats, hamsters and rabbits. There are no adequate and well-controlled studies in pregnant women. Acetazolamide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_8b318348-a0c1-45e3-800f-1d7fe579c6a0"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because of the potential for serious adverse reaction in nursing infants from acetazolamide, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_537ad81e-2667-43ca-83c7-13389858f1a4"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of acetazolamide in pediatric patients has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_f4341891-3884-433b-b2b2-1f422f731497"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions, occurring most often early in therapy, include <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, particularly a "<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>" feeling in the extremities, hearing dysfunction or <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, and occasional instances of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> may occur.</p>
<p>Transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> has been reported. This condition invariably subsides upon diminution or discontinuance of the medication.</p>
<p>Other occasional adverse reactions include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Also see <span class="Bold"><a href="#i4i_info_patients_id_41eea5c9-a960-4dac-9b3f-0458546412c3">PRECAUTIONS: Information for Patients</a></span> for possible reactions common to sulfonamide derivatives. Fatalities have occurred although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> (see <span class="Bold"><a href="#i4i_warnings_id_59defe06-7633-472e-a881-57cfe2b460ce">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_e00887f9-7863-473e-895e-390e08c59710"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No data are available regarding acetazolamide overdosage in humans as no cases of acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> with this drug have been reported. Animal data suggest that acetazolamide is remarkably nontoxic. No specific antidote is known. Treatment should be symptomatic and supportive.</p>
<p><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span>, development of an acidotic state, and central nervous effects might be expected to occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.</p>
<p>Supportive measures are required to restore electrolyte and pH balance. The acidotic state can usually be corrected by the administration of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>Despite its high intraerythrocytic distribution and plasma protein binding properties, acetazolamide may be dialyzable. This may be particularly important in the management of acetazolamide overdosage when complicated by the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_8a5db0f7-35c3-419a-860e-d7a43264b811"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9785596-77c4-4160-88f0-87d873b30c33"></a><a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">Acetazolamide should be used as an adjunct to the usual therapy. The dosage employed in the treatment of <span class="Italics">chronic simple (open-angle) <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></span> ranges from 250 mg to 1 g of acetazolamide per 24 hours, usually in divided doses for amounts over 250 mg. It has usually been found that a dosage in excess of 1 g per 24 hours does not produce an increased effect. In all cases, the dosage should be adjusted with careful individual attention both to symptomatology and ocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>. Continuous supervision by a physician is advisable.</p>
<p>In treatment of secondary <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and in the preoperative treatment of some cases of <span class="Italics">acute congestive (closed-angle) <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>,</span> the preferred dosage is 250 mg every four hours, although some cases have responded to 250 mg twice daily on short-term therapy. In some acute cases, it may be more satisfactory to administer an initial dose of 500 mg followed by 125 or 250 mg every four hours depending on the individual case. A complementary effect has been noted when acetazolamide has been used in conjunction with miotics or mydriatics as the case demanded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6202c3e0-7fdd-480c-a7a1-598e32e4998f"></a><a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">It is not clearly known whether the beneficial effects observed in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> are due to direct inhibition of carbonic anhydrase in the central nervous system or whether they are due to the slight degree of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> produced by the divided dosage. The best results to date have been seen in <span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span> in children. Good results, however, have been seen in patients, both children and adult, in other types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> such as <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>, mixed <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> patterns, myoclonic jerk patterns, etc. The suggested total daily dose is 8 to 30 mg per kg in divided doses. Although some patients respond to a low dose, the optimum range appears to be from 375 to 1000 mg daily. However, some investigators feel that daily doses in excess of 1 g do not produce any better results than a 1 g dose. When acetazolamide tablets are given in combination with other anticonvulsants, it is suggested that the starting dose should be 250 mg once daily in addition to the existing medications. This can be increased to levels as indicated above.</p>
<p>The change from other medications to acetazolamide should be gradual and in accordance with usual practice in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_019144f2-5463-4fda-b71a-ddfdb7383b2a"></a><a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First">For <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, the starting dose is usually 250 to 375 mg once daily in the morning (5 mg/kg). If, after an initial response, the patient fails to continue to lose <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> fluid, do not increase the dose but allow for kidney recovery by skipping medication for a day. </p>
<p>Acetazolamide tablets yield best diuretic results when given on alternate days, or for two days alternating with a day of rest.</p>
<p>Failures in therapy may be due to overdosage or too frequent dosage. The use of acetazolamide does not eliminate the need for other therapy such as digitalis, bed rest, and salt restriction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3eb57c17-a6ce-4817-96d6-35af52df261f"></a><a name="section-10.4"></a><p></p>
<h2>Drug-Induced <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">Recommended dosage is 250 to 375 mg of acetazolamide once a day for one or two days, alternating with a day of rest.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5d789be-d16c-41ee-a71a-2498055318f2"></a><a name="section-10.5"></a><p></p>
<h2>Acute Mountain Sickness</h2>
<p class="First">Dosage is 500 mg to 1000 mg daily, in divided doses. In circumstances of rapid ascent, such as in rescue or military operations, the higher dose level of 1000 mg is recommended. It is preferable to initiate dosing 24 to 48 hours before ascent and to continue for 48 hours while at high altitude, or longer as necessary to control symptoms.</p>
<p>Note: The dosage recommendations for <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> differ considerably from those for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, since the first two conditions are not dependent upon carbonic anhydrase inhibition in the kidney which requires intermittent dosage if it is to recover from the inhibitory effect of the therapeutic agent.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e6e7cbba-45f4-4c71-b80c-04e2343b9dc5"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">AcetaZOLAMIDE Tablets USP are supplied as follows:</p>
<p>125 mg - White, round, scored in half, on one side, "T52" engraved on the other side:</p>
<p>NDC 60429-033-01 - Bottles of 100 Tablets</p>
<p>250 mg - White, round, scored in quarters, on one side, "T53" engraved on the other side:</p>
<p>NDC 60429-034-01 - Bottles of 100 Tablets</p>
<p><span class="Bold">Store at 20°-25°C (68°-77°F). Excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].</span></p>
<p>Mfd. by: <span class="Bold">Taro Pharmaceutical Industries Ltd.</span> Haifa Bay, Israel 26110</p>
<p>Marketed/Packaged by: <span class="Bold">GSMS Inc.</span> Camarillo, CA 93012</p>
<p>Revised: March, 2005</p>
<p>79429-0305-1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a7d397f1-9dd9-4ec2-9b19-4fd0b410ee36"></a><a name="section-12"></a><p></p>
<h1>Principal Panel Display - 125 mg</h1>
<div class="Figure">
<a name="id587"></a><img alt="Label Graphic - 125mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ceb5cac3-bbfb-42fa-8b29-c0ef5ed0913c&amp;name=ceb5cac3-bbfb-42fa-8b29-c0ef5ed0913c-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_27333b9f-82dc-48fe-ad67-f5e5426bc0af"></a><a name="section-13"></a><p></p>
<h1>Principal Panel Display - 250 mg</h1>
<div class="Figure">
<a name="id600"></a><img alt="Label Graphic -  250 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ceb5cac3-bbfb-42fa-8b29-c0ef5ed0913c&amp;name=ceb5cac3-bbfb-42fa-8b29-c0ef5ed0913c-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACETAZOLAMIDE 		
					</strong><br><span class="contentTableReg">acetazolamide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60429-033(NDC:51672-4022)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Acetazolamide</strong> (Acetazolamide) </td>
<td class="formItem">Acetazolamide</td>
<td class="formItem">125 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE B POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T52</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60429-033-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040195</td>
<td class="formItem">05/28/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACETAZOLAMIDE 		
					</strong><br><span class="contentTableReg">acetazolamide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60429-034(NDC:51672-4023)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Acetazolamide</strong> (Acetazolamide) </td>
<td class="formItem">Acetazolamide</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE B POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T53</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60429-034-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040195</td>
<td class="formItem">05/28/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Golden State Medical Supply, Inc.
							(603184490)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Golden State Medical Supply, Inc.</td>
<td class="formItem"></td>
<td class="formItem">603184490</td>
<td class="formItem">REPACK(60429-033, 60429-034), RELABEL(60429-033, 60429-034)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>12b35b09-5630-4720-a28a-eb8a395ee013</div>
<div>Set id: ceb5cac3-bbfb-42fa-8b29-c0ef5ed0913c</div>
<div>Version: 2</div>
<div>Effective Time: 20110701</div>
</div>
</div> <div class="DistributorName">Golden State Medical Supply, Inc.</div></p>
</body></html>
